Australia's CSL is wielding the axe, cutting its workforce by 15% – around 3,000 positions – while announcing plans to spin its vaccines unit into a standalone company. The decision to demerge the CSL ...

A leading investment expert says ASX investors have a rare chance to buy CSL shares at a discount. CSL shares remain down 35.2% over the past year, impacted by concerns over vaccine sales and ...

Three years after introducing Hemgenix, the first gene therapy for hemophilia B, CSL Behring has released long-term data proving the treatment’s benefits remain durable after five years. The five-year ...

Australia's CSL, which earlier this year paused plans to put its CSL Seqirus vaccine division up for sale, has opened the doors to a new $1 billion cell-based influenza vaccine and antivenom ...

uniQure and CSL have become the first pharma companies to get regulatory approval for a gene therapy for haemophilia B anywhere in the world, after the FDA cleared their Hemgenix therapy for adults ...

Accusing CSL of a “disgraceful” approach to bargaining, the CSL Behring workers are taking the protected action as the company puts out a revised offer to workers following the voting down of a ...

Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...

BMW's M division has a new halo car, and it also revives a legendary nameplate. The original BMW 3.0 CSL was a homologation special from the early 1970s, and the 'L' in its name came to signify ...

CSL Limited (CSL), an ASX-listed company, is a global biotechnology company engaged in research, development, manufacture, marketing and distribution of biopharmaceutical products and vaccines.

Bad deals, nasty numbers, big mistakes and the occasional triumph. It’s been one heck of a year for corporate Australia.

Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...